 |
| Vipin K. Garg, Ph.D. |
 |
President & CEO
 Dr.
Garg joined Tranzyme as its President and CEO in September 2000.
He has over 20 years of biotechnology industry experience in
both technical and management positions. Under his leadership,
Tranzyme merged with a Canadian biotechnology company (NEOKIMIA
Inc.) resulting in the formation of Tranzyme Pharma. Prior to
joining Tranzyme, Dr. Garg was Chief Operating Officer at Apex
Bioscience, Inc. (now Curacyte AG of Munich, Germany), where he
was responsible for establishing a major strategic alliance with
a Japanese Pharmaceutical Company and advancing the Company’s
products through clinical development. Earlier he held senior
management positions at DNX, Inc. [NASDAQ: DNXX], Sepracor, Inc.
[NASDAQ: SEPR] and Bio-Response Inc. (acquired by Baxter).
During his career Dr. Garg has been responsible for establishing
a number of corporate alliances and has been involved in several
financings and liquidity events, including mergers and
acquisitions. He has managed operations in US, Europe and
Canada. Dr. Garg serves on the board of the North Carolina
Biotechnology Center. He received his Ph.D. in Biochemistry in
1982 from the University of Adelaide, Australia.
| Helmut
Thomas, Ph.D., DABT |
|
Senior
Vice President, Research & Preclinical Development
 Dr.
Thomas joined Tranzyme Pharma in June 2006. He is a highly
accomplished biochemist and toxicologist with an extensive and
productive career in drug discovery and development. He began
his career with CIBA-GEIGY in Basel, Switzerland in 1990 and
became the Head of Preclinical Safety and Toxicology at
CIBA-GEIGY Pharmaceuticals UK in 1994. Following the merger with
Sandoz in 1997, Dr. Thomas spent the next eight years with
Novartis Pharma, where he held several top-level management
positions in Europe and the U.S., culminating in his appointment
as Executive Director, Global Project Manager and Leader of the
PRIDE (Proof of Research In Development) Team Oncology in East
Hanover, NJ. While at Novartis, he directed the preclinical
development of more than 25 drug candidates, including such
important marketed drugs as Diovan® for hypertension and Gleevec®
for chronic myeloid leukemia. He joined Tranzyme from LymphoSign
Inc., where he served as Vice President, Research and
Development since 2004. Dr. Thomas received his Ph.D. in
biochemistry and organic chemistry from the University of
Hannover, Germany. He is an author of over 130 scientific
articles, book chapters and abstracts as well as a co-inventor
on numerous patents.
|
Gordana Kosutic , M.D. |
|
Vice President, Clinical and Regulatory Affairs
 Dr.
Kosutic is a highly accomplished physician-executive with 25
years of experience in all aspects of pharmaceutical
development, including clinical research, medical and regulatory
affairs and medical marketing. Prior to joining Tranzyme Pharma
in September 2005, Dr. Kosutic served as Vice President of
Clinical Development at Fulcrum Pharma Developments, Inc., Vice
President of Clinical and Regulatory Affairs at both Nobex
Corporation and ClinTrials Research, Inc. (now part of Charles
River Laboratories), and Director of Clinical Research at ICN
Pharmaceuticals, Inc. Her research and clinical experience spans
multiple therapeutic indications including gastrointestinal and
metabolic diseases, osteoporosis, hepatitis, psychiatric
disorders, and cancer. She has extensive clinical development
expertise encompassing strategic development and clinical trial
design and implementation. Dr. Kosutic also actively
participated in special committees for multiple products related
to myocardial infarction, anti-coagulant drugs and anti-diabetic
drugs. She is author or co-author of twenty publications,
abstracted presentations and patents. Dr. Kosutic received her
medical degree from the School of Medicine, University of
Belgrade, Serbia.
| Mark L. Peterson, Ph.D. |
|
Vice President, IP &
Operations
 Dr.
Peterson, a synthetic chemist by training, received his Ph.D. in
Organic Chemistry from Washington State University (Professor D.
Matteson, 1987) on the asymmetric synthesis of chiral natural
products. He conducted post-doctoral research at the University
of Minnesota in the Department of Medicinal Chemistry (Professor
R. Vince) with a focus on the discovery of new antiviral and
antitumor chemotherapeutic agents. In 1989, he received a
National Service Award from the National Institute of Health
(US). Starting in 1990, he joined the Agricultural Division of
Monsanto Co. (St. Louis, MO, USA) where he was involved in a
number of aspects of the R & D process, including constructing a
novel class of inhibitors for EPSP synthase and directing
regulatory studies to support the registration of a new
herbicide product. In 1993, Dr. Peterson moved to Advanced
ChemTech (Louisville, KY, USA), where he served in areas of
increasing responsibility, culminating as Corporate
Vice-President of Technology Development. While with ACT, he
initiated R & D efforts in automated combinatorial library
synthesis and solid phase organic chemistry. With Tranzyme
Pharma since 1999, Dr. Peterson led the chemistry R & D efforts
during the technology development stage of the Company and the
start of its drug discovery programs. He is author or co-author
of over eighty publications, abstracted presentations and
patents plus one book chapter.
| Richard I. Eisenstadt, M.B.A. |
|
Vice President, Finance
and Chief Financial Officer
 Mr.
Eisenstadt has extensive experience in working with technology
companies in both public and private markets. Prior to joining
Tranzyme in June 2003, he served as senior financial advisor to
several biotechnology companies with responsibilities including
business and strategic planning, fundraising and financial
reporting. He spent over two years as Director of Finance at
Cogent Neuroscience where he was responsible for financial
operations, including the establishment of two international
joint ventures. Before Cogent, he spent twelve years with Nimbus
CD International, where he was responsible for strategic and
financial planning and ensuring that adequate financing was in
place to meet aggressive growth plans. His experience at Nimbus
included guiding the company through an LBO, a recapitalization,
an IPO, a reverse merger and several debt refinancings. Also,
while at Nimbus, Mr. Eisenstadt established an international
joint venture and was involved in several domestic and
international acquisition and expansion opportunities.
|
|
|
